Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $32.40.

A number of research firms have commented on BCAX. Guggenheim initiated coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. Wedbush increased their target price on Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. The Goldman Sachs Group lifted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Mizuho boosted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Finally, Wells Fargo & Company increased their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the sale, the chief operating officer owned 181,641 shares of the company’s stock, valued at approximately $5,082,315.18. The trade was a 9.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the completion of the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at approximately $10,133,012.96. The trade was a 2.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 117,200 shares of company stock valued at $3,267,100 in the last quarter. 13.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics during the fourth quarter worth about $45,000. Legal & General Group Plc boosted its holdings in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Larson Financial Group LLC grew its position in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares in the last quarter.

Bicara Therapeutics Price Performance

BCAX stock opened at $24.94 on Tuesday. Bicara Therapeutics has a 12 month low of $10.30 and a 12 month high of $30.99. The firm’s 50-day moving average is $26.24 and its 200 day moving average is $21.90. The company has a market capitalization of $1.65 billion, a PE ratio of -8.05 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.82). Sell-side analysts forecast that Bicara Therapeutics will post -3.45 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.